Search Results
Dr. Birrer on PARP Inhibitors in Ovarian Cancer
Dr. Birrer on PARP Inhibitors in Ovarian Cancer
Michael J. Birrer, MD, PhD, considers the benefits of various PARP inhibitors in ovarian cancer
Dr. Birrer on FDA Approval of Rucaparib in Ovarian Cancer
ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies
PARP Inhibition in Ovarian Cancer
Michael Birrer, MD, on the key takeaways from the ovarian plenary session in ovarian cancer
Predicting Response to PARP Inhibitor Therapy in Ovarian Cancer
PARP Inhibitors in Recurrent Ovarian Cancer
Michael J. Birrer MD, PhD: Future of Ovarian Cancer Treatment: Personalized Medicine
Expert Perspectives: The Clinical Potential of PARP Inhibitors in Ovarian Cancer
Michael J. Birrer, MD, PhD, on the role of maintenance therapy in newly diagnosed ovarian cancer
